The impact of irritable bowel syndrome on health-related quality of life in women with polycystic ovary syndrome.
Irritable bowel syndrome
Polycystic ovary syndrome
Quality of life
Journal
Health and quality of life outcomes
ISSN: 1477-7525
Titre abrégé: Health Qual Life Outcomes
Pays: England
ID NLM: 101153626
Informations de publication
Date de publication:
13 Jul 2020
13 Jul 2020
Historique:
received:
13
06
2019
accepted:
02
06
2020
entrez:
15
7
2020
pubmed:
15
7
2020
medline:
3
11
2020
Statut:
epublish
Résumé
The objectives of this study were to compare the prevalence and quality of life (QOL) of irritable bowel syndrome (IBS) in women with polycystic ovary syndrome (PCOS) compared with healthy women. This was a case-control study of 201 women recruited at an infertility clinic in Iran. The control group were healthy women (n = 100) and the comparison group, women with PCOS (n = 101). Data were collected by clinical Rome III criteria to determine the IBS, Bristol scale for stool consistency and IBS QOL. The reporting of IBS symptoms were higher in PCOS (20.7%) than control group (11%) (P = 0.05). The IBS QOL score in the IBS + PCOS group was lower than other groups (IBS+ non PCOS, non IBS + PCOS, non IBS+ non PCOS; scores in food avoidance and worries about health domains were significant (P < 0.01). We conclude that having PCOS and an increased level of LH/FSH tends to cause IBS symptoms. IBS + PCOS women experience significant impaired quality of life scores particularly in relation to worries about health and food avoidance. These results offer further insights into IBS in PCOS women and their functional status and wellbeing.
Sections du résumé
BACKGROUND
BACKGROUND
The objectives of this study were to compare the prevalence and quality of life (QOL) of irritable bowel syndrome (IBS) in women with polycystic ovary syndrome (PCOS) compared with healthy women.
METHODS
METHODS
This was a case-control study of 201 women recruited at an infertility clinic in Iran. The control group were healthy women (n = 100) and the comparison group, women with PCOS (n = 101). Data were collected by clinical Rome III criteria to determine the IBS, Bristol scale for stool consistency and IBS QOL.
RESULTS
RESULTS
The reporting of IBS symptoms were higher in PCOS (20.7%) than control group (11%) (P = 0.05). The IBS QOL score in the IBS + PCOS group was lower than other groups (IBS+ non PCOS, non IBS + PCOS, non IBS+ non PCOS; scores in food avoidance and worries about health domains were significant (P < 0.01).
CONCLUSIONS
CONCLUSIONS
We conclude that having PCOS and an increased level of LH/FSH tends to cause IBS symptoms. IBS + PCOS women experience significant impaired quality of life scores particularly in relation to worries about health and food avoidance. These results offer further insights into IBS in PCOS women and their functional status and wellbeing.
Identifiants
pubmed: 32660493
doi: 10.1186/s12955-020-01428-7
pii: 10.1186/s12955-020-01428-7
pmc: PMC7358924
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
226Subventions
Organisme : Hormozgan University of Medical Sciences
ID : 95135
Références
Am J Gastroenterol. 1998 Oct;93(10):1816-22
pubmed: 9772037
Eur J Gastroenterol Hepatol. 2007 Dec;19(12):1097-103
pubmed: 17998835
Gut. 1992 Jun;33(6):825-30
pubmed: 1624167
J Clin Endocrinol Metab. 1961 Nov;21:1440-7
pubmed: 13892577
J Neurogastroenterol Motil. 2010 Jan;16(1):61-70
pubmed: 20535328
Iran J Reprod Med. 2013 Sep;11(9):753-60
pubmed: 24639816
Obstet Gynecol. 1999 Sep;94(3):337-40
pubmed: 10472855
Fertil Steril. 2005 Apr;83(4):1012-20
pubmed: 15820814
Pharmacoeconomics. 2001;19(6):643-53
pubmed: 11456212
J Sex Med. 2014 Apr;11(4):1023-1032
pubmed: 24308752
J Gastroenterol Hepatol. 2009 Dec;24(12):1885-90
pubmed: 19780881
Obstet Gynecol Surv. 2006 Nov;61(11):723-32
pubmed: 17044949
BMJ. 2006 Feb 4;332(7536):280-3
pubmed: 16455728
Am J Gastroenterol. 2001 Jul;96(7):2184-93
pubmed: 11467651
Int J Fertil Steril. 2014 Oct;8(3):273-80
pubmed: 25379156
Biol Res Nurs. 2003 Jul;5(1):56-65
pubmed: 12886671
Hum Reprod. 2012 Sep;27(9):2729-36
pubmed: 22740491
J Gastrointestin Liver Dis. 2006 Sep;15(3):237-41
pubmed: 17013448
Clin Endocrinol (Oxf). 2008 Dec;69(6):831-44
pubmed: 18616705
Health Qual Life Outcomes. 2013 Aug 16;11:141
pubmed: 23947827
Scand J Gastroenterol. 1997 Sep;32(9):920-4
pubmed: 9299672
Am J Gastroenterol. 2009 Jan;104 Suppl 1:S1-35
pubmed: 19521341
Am J Gastroenterol. 2002 Dec;97(12):3204; author reply 3204-5
pubmed: 12492215
Dig Dis Sci. 2010 Apr;55(4):1085-9
pubmed: 19697132
Saudi J Gastroenterol. 2010 Jul-Sep;16(3):154-60
pubmed: 20616409
Br Med J (Clin Res Ed). 1988 Jun 18;296(6638):1710
pubmed: 3135889
Fertil Steril. 2013 Nov;100(5):1389-96
pubmed: 23891270
Z Gastroenterol. 2002 Oct;40(10):863-7
pubmed: 12436352
Iran J Reprod Med. 2013 May;11(5):371-8
pubmed: 24639768
Iran J Reprod Med. 2013 Oct;11(10):829-36
pubmed: 24639704
Int J Colorectal Dis. 2007 Jul;22(7):791-9
pubmed: 17063321
Manag Care Interface. 2004 Feb;17(2):24-8, 34
pubmed: 15038690
Gastroenterology. 2002 Nov;123(5):1686-701
pubmed: 12404243
Acta Med Iran. 2015 Nov;53(11):717-24
pubmed: 26786994
Clin Ther. 2002 Apr;24(4):675-89; discussion 674
pubmed: 12017411